SUNPLUS

Sunplus Biotech is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for cancer and immunological diseases. The company focuses on multi-functional biologics and small molecules that modulate the tumor microenvironment to overcome resistance to current immunotherapies. Its lead program, SP-002, is a bifunctional fusion protein targeting PD-L1 and TGF-β, designed to simultaneously block immune evasion and suppressive signaling in the tumor stroma. Sunplus Biotech leverages its proprietary technology platforms to build a robust pipeline of candidates for patients with high unmet medical needs. The company is headquartered in Suzhou, China, and maintains a strong focus on global clinical development.